Khwaja Fareed University of Engineering & Information Technology (KFUEIT), Rahim Yar Khan, Pakistan
In laboratories across the world, a quiet revolution is unfolding. Algorithms are sifting through billions of molecular combinations, predicting protein structures in minutes, and identifying potential drug candidates faster than any human team ever could. The promise is intoxicating: diseases cured in years instead of decades, personalized medicine tailored to each individual, and a future where diagnosis is nearly instantaneous. Yet beneath this optimism lies a more complicated reality—one that demands careful scrutiny, especially for countries like Pakistan navigating fragile research ecosystems. Artificial intelligence has undeniably altered the architecture of modern drug discovery. Traditionally, bringing a new drug to market could take 10 to 15 years and cost billions of dollars, with a high probability of failure. AI compresses this timeline by rapidly screening compounds, simulating biological interactions, and identifying viable candidates with unprecedented speed. In fields like oncology and antibiotic resistance, early results are promising. Machine learning systems have identified novel antibiotics and accelerated vaccine design, particularly during global health crises.
However, the central question remains unresolved: if AI is so powerful, why have we not yet witnessed a truly transformative, AI-designed drug dominating clinical practice? The answer lies in the gap between computational prediction and biological reality. AI excels in pattern recognition, but human biology is not merely a dataset—it is a dynamic, nonlinear system shaped by genetics, environment, and randomness. Many AI-generated drug candidates fail when they encounter the complexity of real-world clinical trials. In other words, AI can suggest possibilities, but it cannot yet guarantee outcomes. This distinction is critical because much of the current discourse is driven by narrative rather than evidence. Venture capital flows, corporate announcements, and media headlines often project AI as a near-miraculous solution to healthcare challenges. Yet regulatory approvals, long-term safety data, and large-scale clinical validation remain bottlenecks that no algorithm can bypass. The risk, therefore, is not that AI will fail—but that expectations will outpace reality, leading to disillusionment or misallocated resources.
For Pakistan, this global shift presents both an opportunity and a warning.
At present, the country’s research and development (R&D) expenditure remains below 1% of GDP, significantly lagging behind innovation-driven economies. Universities, despite pockets of excellence, often struggle with limited funding, outdated infrastructure, and weak industry linkages. The Higher Education Commission (HEC) has made commendable efforts to promote research culture, quality assurance, and international collaboration, but the scale of transformation required in the age of AI-driven science is far greater. The integration of AI into biomedical research demands more than just computational tools—it requires interdisciplinary ecosystems. Data scientists must collaborate with biologists, chemists with computer engineers, clinicians with statisticians. Unfortunately, Pakistan’s academic structures remain largely siloed. Departments operate in isolation, curricula lag behind emerging technologies, and incentives often prioritize publication quantity over translational impact.
This is where policy intervention becomes crucial.
First, there is an urgent need to redefine research priorities. Instead of pursuing fragmented, low-impact studies, universities must align with national health challenges—such as infectious diseases, maternal health, and non-communicable diseases—while leveraging AI as an enabling tool. Funding mechanisms should reward collaborative, problem-oriented research rather than individual academic output. Second, capacity building must move beyond conventional training. Pakistan needs a new generation of scientists fluent in both domain knowledge and computational thinking. This requires curriculum reform at undergraduate and postgraduate levels, integrating AI, data analytics, and bioinformatics into core science education. Short-term workshops and certifications are not enough; systemic change is needed. Third, industry-academia linkages must be strengthened. In advanced economies, pharmaceutical companies, research institutions, and startups operate in a tightly connected ecosystem. In Pakistan, this linkage is weak or, in many cases, non-existent. Without industry engagement, AI-driven discoveries will remain confined to academic publications rather than translating into tangible healthcare solutions. Fourth, data infrastructure must be prioritized. AI thrives on data, yet Pakistan lacks robust, standardized, and accessible healthcare datasets. Electronic health records are fragmented, and data-sharing frameworks are underdeveloped. Establishing national biomedical data repositories—while ensuring privacy and ethical safeguards—could significantly enhance research capacity. Equally important is the ethical dimension. AI in healthcare raises questions about data ownership, algorithmic bias, and equitable access. If left unchecked, these technologies could deepen existing inequalities, benefiting only those who can afford advanced treatments. Policymakers must ensure that innovation does not come at the cost of inclusivity.
Globally, the trajectory of AI in drug discovery is clear: it will play a transformative role, but not in isolation. The future of medicine will be shaped by a hybrid model—where human expertise and machine intelligence complement each other. The narrative of “AI replacing scientists” is not only misleading but counterproductive. The real challenge is building systems where AI augments human capability rather than overshadowing it.
For Pakistan, the stakes are particularly high. The country stands at a crossroads: it can either remain a passive consumer of imported technologies or emerge as an active participant in the global knowledge economy. The difference will depend on strategic vision, institutional reform, and sustained investment in science and innovation. The allure of AI curing diseases is powerful, and not without merit. But breakthroughs are not born from algorithms alone—they emerge from ecosystems that nurture curiosity, collaboration, and critical thinking. Without these foundations, even the most advanced technologies will fail to deliver meaningful impact. The world may indeed be moving toward an era where diseases are predicted, prevented, and treated with unprecedented precision. But the timeline of that future will not be determined by algorithms—it will be determined by the choices we make today. And for countries like Pakistan, the real question is not whether AI will cure diseases, but whether we will build the capacity to be part of that cure—or remain dependent on those who do.
